NRSN vs. MNOV, GNTA, CUE, ANL, GANX, CVM, HOWL, IZTC, ADVM, and INKT
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include MediciNova (MNOV), Genenta Science (GNTA), Cue Biopharma (CUE), Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), Invizyne Technologies (IZTC), Adverum Biotechnologies (ADVM), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs. Its Competitors
NeuroSense Therapeutics (NASDAQ:NRSN) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.
NeuroSense Therapeutics' return on equity of 0.00% beat MediciNova's return on equity.
NeuroSense Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 1,093.52%. MediciNova has a consensus price target of $7.00, indicating a potential upside of 433.37%. Given NeuroSense Therapeutics' higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than MediciNova.
NeuroSense Therapeutics has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeuroSense Therapeutics had 3 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 1 mentions for MediciNova. MediciNova's average media sentiment score of 0.78 beat NeuroSense Therapeutics' score of -0.02 indicating that MediciNova is being referred to more favorably in the news media.
NeuroSense Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 13.6% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
NeuroSense Therapeutics beats MediciNova on 7 of the 13 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access